Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B A Chabner

Showing results (51-60 of 245) with videos related to

Pageof 25
Sort By:
Public Health Reports (Washington, D.C. : 1974)|July 1, 1984
Investigational trials of anticancer drugs: establishing safeguards for experimentationB A Chabner, R Wittes, D Hoth, et al.
Biochemical Pharmacology|January 1, 1977
Characteristics of the enzyme uridine-cytidine kinase isolated from a cultured human cell lineJ C Drake, R G Stoller, B A Chabner
Annals of the New York Academy of Sciences|August 8, 1975
Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cellsC N Coleman, D G Johns, B A Chabner
Annals of Internal Medicine|July 1, 1983
Campylobacter thrombophlebitisD B Geffen, V J Gill, B A Chabner
Cancer Research|June 1, 1981
Postchemotherapy purine excretion in lymphoma patients receiving allopurinolK R Hande, C V Hixson, B A Chabner
Cancer Treatment Reports|January 1, 1979
Phase II study of high-dose methotrexate in patients with advanced malignant melanomaR I Fisher, B A Chabner, C E Myers
Biochimica Et Biophysica Acta|November 9, 1979
Isolation and identification of a small molecular weight inhibitor of cyclic nucleotide phosphodiesterase from bovine brainC M Liang, Y P Liu, B A Chabner
Seminars in Oncology|June 1, 1977
Clinical pharmacology of anticancer drugsB A Chabner, C E Myers, V T Oliverio
Life Sciences|July 2, 1979
New developments on the mechanisms of action of antineoplastic drugsR C Donehower, C E Myers, B A Chabner
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1996
Cancer chemotherapy and biological response modifiers annual 16. IntroductionH M Pinedo, D L Longo, B A Chabner
Pageof 25

Showing results (51-60 of 245) with videos related to

Sort By:
Pageof 25
Public Health Reports (Washington, D.C. : 1974)|July 1, 1984
Investigational trials of anticancer drugs: establishing safeguards for experimentationB A Chabner, R Wittes, D Hoth, et al.
Biochemical Pharmacology|January 1, 1977
Characteristics of the enzyme uridine-cytidine kinase isolated from a cultured human cell lineJ C Drake, R G Stoller, B A Chabner
Annals of the New York Academy of Sciences|August 8, 1975
Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cellsC N Coleman, D G Johns, B A Chabner
Annals of Internal Medicine|July 1, 1983
Campylobacter thrombophlebitisD B Geffen, V J Gill, B A Chabner
Cancer Research|June 1, 1981
Postchemotherapy purine excretion in lymphoma patients receiving allopurinolK R Hande, C V Hixson, B A Chabner
Cancer Treatment Reports|January 1, 1979
Phase II study of high-dose methotrexate in patients with advanced malignant melanomaR I Fisher, B A Chabner, C E Myers
Biochimica Et Biophysica Acta|November 9, 1979
Isolation and identification of a small molecular weight inhibitor of cyclic nucleotide phosphodiesterase from bovine brainC M Liang, Y P Liu, B A Chabner
Seminars in Oncology|June 1, 1977
Clinical pharmacology of anticancer drugsB A Chabner, C E Myers, V T Oliverio
Life Sciences|July 2, 1979
New developments on the mechanisms of action of antineoplastic drugsR C Donehower, C E Myers, B A Chabner
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1996
Cancer chemotherapy and biological response modifiers annual 16. IntroductionH M Pinedo, D L Longo, B A Chabner
Pageof 25